These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 28302482)
1. FAP positive fibroblasts induce immune checkpoint blockade resistance in colorectal cancer via promoting immunosuppression. Chen L; Qiu X; Wang X; He J Biochem Biophys Res Commun; 2017 May; 487(1):8-14. PubMed ID: 28302482 [TBL] [Abstract][Full Text] [Related]
2. Fibroblast Activation Protein-α-Positive Fibroblasts Promote Gastric Cancer Progression and Resistance to Immune Checkpoint Blockade. Wen X; He X; Jiao F; Wang C; Sun Y; Ren X; Li Q Oncol Res; 2017 Apr; 25(4):629-640. PubMed ID: 27983931 [TBL] [Abstract][Full Text] [Related]
3. FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling. Yang X; Lin Y; Shi Y; Li B; Liu W; Yin W; Dang Y; Chu Y; Fan J; He R Cancer Res; 2016 Jul; 76(14):4124-35. PubMed ID: 27216177 [TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Kakarla S; Chow KK; Mata M; Shaffer DR; Song XT; Wu MF; Liu H; Wang LL; Rowley DR; Pfizenmaier K; Gottschalk S Mol Ther; 2013 Aug; 21(8):1611-20. PubMed ID: 23732988 [TBL] [Abstract][Full Text] [Related]
5. Improvement of anti-tumor immunity of fibroblast activation protein α based vaccines by combination with cyclophosphamide in a murine model of breast cancer. Xia Q; Zhang FF; Geng F; Liu CL; Wang YQ; Xu P; Lu ZZ; Xie Y; Wu H; Chen Y; Zhang Y; Kong W; Yu XH; Zhang HH Cell Immunol; 2016 Dec; 310():89-98. PubMed ID: 27545090 [TBL] [Abstract][Full Text] [Related]
6. Immunization of stromal cell targeting fibroblast activation protein providing immunotherapy to breast cancer mouse model. Meng M; Wang W; Yan J; Tan J; Liao L; Shi J; Wei C; Xie Y; Jin X; Yang L; Jin Q; Zhu H; Tan W; Yang F; Hou Z Tumour Biol; 2016 Aug; 37(8):10317-27. PubMed ID: 26842926 [TBL] [Abstract][Full Text] [Related]
7. Enhancement of fibroblast activation protein α-based vaccines and adenovirus boost immunity by cyclophosphamide through inhibiting IL-10 expression in 4T1 tumor bearing mice. Xia Q; Geng F; Zhang FF; Liu CL; Xu P; Lu ZZ; Zhang HH; Kong W; Yu XH Vaccine; 2016 Aug; 34(38):4526-4535. PubMed ID: 27498213 [TBL] [Abstract][Full Text] [Related]
8. Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model. Wang W; Wu L; Zhang J; Wu H; Han E; Guo Q Biochem Biophys Res Commun; 2017 May; 487(1):1-7. PubMed ID: 28042031 [TBL] [Abstract][Full Text] [Related]
9. Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer. Sandberg TP; Stuart MPME; Oosting J; Tollenaar RAEM; Sier CFM; Mesker WE BMC Cancer; 2019 Mar; 19(1):284. PubMed ID: 30922247 [TBL] [Abstract][Full Text] [Related]
10. Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice. Duperret EK; Trautz A; Ammons D; Perales-Puchalt A; Wise MC; Yan J; Reed C; Weiner DB Clin Cancer Res; 2018 Mar; 24(5):1190-1201. PubMed ID: 29269377 [No Abstract] [Full Text] [Related]
11. A vaccine that co-targets tumor cells and cancer associated fibroblasts results in enhanced antitumor activity by inducing antigen spreading. Gottschalk S; Yu F; Ji M; Kakarla S; Song XT PLoS One; 2013; 8(12):e82658. PubMed ID: 24349329 [TBL] [Abstract][Full Text] [Related]
12. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. Tran E; Chinnasamy D; Yu Z; Morgan RA; Lee CC; Restifo NP; Rosenberg SA J Exp Med; 2013 Jun; 210(6):1125-35. PubMed ID: 23712432 [TBL] [Abstract][Full Text] [Related]
13. Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma. Gunderson AJ; Yamazaki T; McCarty K; Phillips M; Alice A; Bambina S; Zebertavage L; Friedman D; Cottam B; Newell P; Gough MJ; Crittenden MR; Van der Veken P; Young KH PLoS One; 2019; 14(2):e0211117. PubMed ID: 30726287 [TBL] [Abstract][Full Text] [Related]
14. Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade. Zhao L; Pang Y; Zhou Y; Chen J; Fu H; Guo W; Xu W; Xue X; Su G; Sun L; Wu H; Zhang J; Wang Z; Lin Q; Chen X; Chen H Signal Transduct Target Ther; 2024 Jun; 9(1):142. PubMed ID: 38825657 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety evaluation of cross-reactive Fibroblast activation protein scFv-based CAR-T cells. Niu W; Wang B; Zhang Y; Wang C; Cao J; Li J; He Y; Lei P Front Immunol; 2024; 15():1433679. PubMed ID: 39086477 [TBL] [Abstract][Full Text] [Related]
16. The application of the fibroblast activation protein α-targeted immunotherapy strategy. Jiang GM; Xu W; Du J; Zhang KS; Zhang QG; Wang XW; Liu ZG; Liu SQ; Xie WY; Liu HF; Liu JS; Wu BP Oncotarget; 2016 May; 7(22):33472-82. PubMed ID: 26985769 [TBL] [Abstract][Full Text] [Related]
17. Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody-Drug Conjugate Targeting Fibroblast Activation Protein. Gallant JP; Hintz HM; Gunaratne GS; Breneman MT; Recchia EE; West JL; Ott KL; Heninger E; Jackson AE; Luo NY; Rosenkrans ZT; Hernandez R; Zhao SG; Lang JM; Meimetis L; Kosoff D; LeBeau AM Cancer Res Commun; 2024 Jun; 4(6):1481-1494. PubMed ID: 38747612 [TBL] [Abstract][Full Text] [Related]
18. Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment. Lin Y; Li B; Yang X; Cai Q; Liu W; Tian M; Luo H; Yin W; Song Y; Shi Y; He R Neoplasia; 2019 Dec; 21(12):1133-1142. PubMed ID: 31759251 [TBL] [Abstract][Full Text] [Related]
19. Altered expression of fibroblast activation protein-α (FAP) in colorectal adenoma-carcinoma sequence and in lymph node and liver metastases. Solano-Iturri JD; Beitia M; Errarte P; Calvete-Candenas J; Etxezarraga MC; Loizate A; Echevarria E; Badiola I; Larrinaga G Aging (Albany NY); 2020 May; 12(11):10337-10358. PubMed ID: 32428869 [TBL] [Abstract][Full Text] [Related]
20. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis. Hu S; Ma J; Su C; Chen Y; Shu Y; Qi Z; Zhang B; Shi G; Zhang Y; Zhang Y; Huang A; Kuang Y; Cheng P Acta Biomater; 2021 Nov; 135():567-581. PubMed ID: 34506976 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]